JPRN-jRCT2031220191
Recruiting
Phase 4
Special drug use-results surveillance of Scemblix Tablets(resistant or intolerant chronic myeloid leukemia)
Toshiya Sugimoto0 sites440 target enrollmentJuly 7, 2022
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Chronic myeloid leukemia resistant or intolerant to pretreatment drugs
- Sponsor
- Toshiya Sugimoto
- Enrollment
- 440
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All patients treated with asciminib
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Special drug use-results surveillance <Patients with cold agglutinin disease>Cold agglutinin diseaseJPRN-UMIN000049607sanofi K.K.100
Recruiting
Not Applicable
Special Drug Use Results Surveillance for the use of Odefsey in pregnant womeHIV/AIDSJPRN-UMIN000034028Janssen Pharmaceutical K.K.3
Completed
Not Applicable
Special drug use results surveillance for the use of SIMPONI in ulcerative colitisulcerative colitisJPRN-UMIN000027542Janssen Pharmaceutical K.K.300
Completed
Not Applicable
Special Drug Use-results Surveillance of Scemblix TabletsChronic Myeloid LeukemiaNCT05421091Novartis Pharmaceuticals550
Completed
Not Applicable
Special Drug Use-results Surveillance for long term administration in adult (18 years and older) of CONCERTA, 18mg/ 27mg/ 36mg TabletsAttention deficit hyperactivity disorder (ADHD)JPRN-UMIN000015900Janssen Pharmaceutical K.K500